Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott (NYSE: ABT) received FDA clearance and a CE Mark for Ultreon 3.0, its next-generation AI-powered coronary imaging platform, on April 28, 2026. Ultreon 3.0 combines high-resolution OCT imaging, a one-second OCT pullback, and AI-automated insights to support planning, stent sizing, and post-procedure assessment for complex PCI.
The platform aims to speed workflows, reduce contrast use (relevant for ~25% of CAD patients with kidney disease), and provide real-time guidance to clinicians treating complex coronary artery disease.
Abbott (NYSE: ABT) presented four late-breaking clinical datasets at Heart Rhythm Society 2026 showing positive outcomes for pulsed field ablation (PFA) and conduction system pacing (CSP) technologies.
Key six-month and early follow-up results: TactiFlex Duo showed 87% arrhythmia-free and 98.3% safety in 188 patients; Volt PFA reported efficient treatment (4.1 applications per vein; 10.7 per PWI) with no procedure-related complications; CSP leads (UltiSynq and AVEIR) showed high implantation success, strong safety metrics, and stable early electrical performance.
Abbott (NYSE: ABT) reported AACR 2026 data showing its Cancerguard multi-cancer early detection test uses a multi-biomarker methylation-plus-protein approach to improve detection across stages. In a case-control study, signals were 47.1% methylation-only, 7.4% protein-only, 45.5% combined; false positives were 2.6% and none were positive for both markers. The AACR award noted DETECT-A multiyear outcomes with ~4-year median follow-up, where treated stage I–II patients remained alive and cancer-free.
Abbott (NYSE: ABT) reported 1Q26 sales of $11,164 million (reported) and comparable sales growth of 3.7%. GAAP diluted EPS was $0.61; adjusted diluted EPS was $1.15. Abbott completed the acquisition of Exact Sciences on March 23, 2026.
Full-year 2026 guidance: comparable sales growth of 6.5%–7.5% and adjusted diluted EPS of $5.38–$5.58, which includes $0.20 dilution from Exact Sciences. Quarterly dividend of $0.63 payable May 15, 2026.
Abbott (NYSE: ABT) released a national survey (April 9, 2026) finding 74% of U.S. adults believe most chronic diseases are preventable, yet only 1 in 4 feel very confident managing their health.
The survey of 4,000 U.S. adults highlights confusion from conflicting guidance, cost barriers, generational differences, and Abbott's partnership with Sesame Workshop to provide free healthy-habit resources.
Abbott (NYSE: ABT) and Flatiron Health integrated Abbott's Precision Oncology portfolio into Flatiron's OncoEMR on March 30, 2026. The integration lets clinicians order Abbott tests and receive results inside the OncoEMR workflow, expanding access across Flatiron's network of 1,600+ community cancer centers and 4,700 providers.
This single, unified experience covers Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard®, aiming to reduce administrative burden and accelerate informed treatment decisions in community oncology settings.
Abbott (NYSE: ABT) will report first-quarter 2026 financial results on Thursday, April 16, 2026, before the market opens. The results will be followed by a live earnings conference call and webcast at 8:00 a.m. Central / 9:00 a.m. Eastern.
According to the company, the webcast will be accessible via Abbott's investor relations website and an archived edition will be available later that day.
Abbott (NYSE: ABT) launched "The (Second) Talk" campaign on March 24, 2026, reuniting John Stamos and Jodie Sweetin to encourage colorectal cancer screening for adults 45 and older.
The campaign promotes the FDA-approved Cologuard test as a noninvasive, at-home screening option; a clinical study reports Cologuard Plus detected 95% of colon cancers.
Abbott (NYSE: ABT) completed its acquisition of Exact Sciences on March 23, 2026, making Exact Sciences a wholly owned Abbott subsidiary and ending Exact Sciences' Nasdaq trading on March 20, 2026.
The deal adds a comprehensive cancer screening and precision oncology portfolio — including Cologuard, Oncotype DX, Oncodetect and Cancerguard — and positions Abbott to serve millions more and lead in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments.
Abbott (NYSE: ABT) expects to close its acquisition of Exact Sciences on March 23, 2026 after receiving all required regulatory clearances. The deal adds cancer screening and precision oncology capabilities, including Cologuard and Oncotype DX, and is expected to contribute ~$3 billion of incremental sales in 2026.
The transaction is projected to accelerate Abbott's 2026 sales growth by ~0.5 percentage points and dilute 2026 adjusted EPS by ~$0.20.